OVERVIEW OF INFLAMMATORY BOWEL DISEASES
Main Article Content
Keywords
Inflammatory bowel diseases, Ulcerative colitis, Crohn’s disease etc
Abstract
Introduction: Inflammatory bowel diseases (IBDs) are complex, long-term inflammatory disorders of the gastrointestinal (GI) tract with an unknown etiology. IBDs are made up of ulcerative colitis (UC) and Crohn's disease (CD), two idiopathic disorders. Though the exact cause, course, and severity of these disorders remain unknown, it is believed that a variety of factors, including genetic, environmental, immunological, physiological, psychological, and gut microbiome factors, interact to influence these aspects of the disease.
Aim of the Study: This present review discusses the diagnosis, treatment, and oversight of inflammatory bowel disease. It also highlights the importance of the interprofessional team in enhancing patient outcomes.
Methodology: The present review is a comprehensive research of PUBMED since the year 1991 to 2022.
Conclusion: Inflammatory bowel disease (IBD) is an idiopathic disease that results in an immunological response to the host's intestinal microbiota that is dysregulated. Research on variables influencing the onset and severity of IBDs has attracted a lot of attention in the last few decades. It is becoming more evident that a variety of factors, including genetic, environmental, psychological, autonomic, immunological, and gut microbiota, interact and contribute to the disease manifestations and persistence of inflammatory bowel diseases (IBDs), even though the genesis of these illnesses is not fully understood. The role of genetic susceptibility and its probable co-dependency with other mediators, such as environmental, immune, and microbial factors, has been highlighted.
References
2. Neurath M F, & Schürmann G (2000). Immunopathogenesis of inflammatory bowel diseases. Der Chirurg, 71, 30-40.
3. Molodecky N A, Soon S, Rabi D M, Ghali W A, Ferris M, Chernoff G, & Kaplan G G (2012). Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology, 142(1), 46-54.
4. Loftus Jr E V (2004). Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology, 126(6), 1504-1517.
5. Roth M P, Petersen G M, McElree C, Feldman E, & Rotter J I (1989). Geographic origins of Jewish patients with inflammatory bowel disease. Gastroenterology, 97(4), 900-904.
6. Sonnenberg A, McCarty D J, & Jacobsen S J (1991). Geographic variation of inflammatory bowel disease within the United States. Gastroenterology, 100(1), 143-149.
7. Su H J, Chiu Y T, Chiu C T, Lin Y C, Wang C Y, Hsieh J Y, & Wei S C (2019). Inflammatory bowel disease and its treatment in 2018: Global and Taiwanese status updates. Journal of the Formosan Medical Association, 118(7), 1083-1092.
8. Yeshi K, Ruscher R, Hunter L, Daly N L, Loukas A, & Wangchuk P (2020). Revisiting inflammatory bowel disease: pathology, treatments, challenges and emerging therapeutics including drug leads from natural products. Journal of Clinical Medicine, 9(5), 1273.
9. "Inflammatory Bowel Disease: An Overview." Journal of The National Medical Association, 114 (2022).:S54-S54. doi: 10.1016/j.jnma.2021.08.030
10. Carey W D (Ed.) (2010). Current clinical medicine. MDConsult [prod.].
11. Raphael I, Nalawade S, Eagar T N, & Forsthuber T G (2015). T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine, 74(1), 5-17.
12. Sartor R B (2006). Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nature clinical practice Gastroenterology & hepatology, 3(7), 390-407.
13. Marsal J, & Agace W W (2012). Targeting T‐cell migration in inflammatory bowel disease. Journal of internal medicine, 272(5), 411-429.
14. De Mattos B R, Garcia M P, Nogueira J B, Paiatto L N, Albuquerque C G, Souza C L, & Simioni P U (2015). Inflammatory bowel disease: an overview of immune mechanisms and biological treatments. Mediators Inflamm, 2015(493012), 493012.
15. Bernstein C N, Fried M, Krabshuis J H, Cohen H, Eliakim R, Fedail S, & Watermeyer G (2010). World Gastroenterology Organisation Global Guideline: Inflammatory bowel disease: a global perspective-June 2009. South African Gastroenterology Review, 8(2).
16. Antonelli E, Bassotti G, Tramontana M, Hansel K, Stingeni L, Ardizzone S, & Maconi G (2021). Dermatological manifestations in inflammatory bowel diseases. Journal of clinical medicine, 10(2), 364.
17. Lee J S, Kim E S, & Moon W (2019). Chronological review of endoscopic indices in inflammatory bowel disease. Clinical endoscopy, 52(2), 129.
18. Morris M S, & Chu D I (2015). Imaging for inflammatory bowel disease. Surgical Clinics, 95(6), 1143-1158.
19. Amodeo G, Franchi S, Galimberti G, Riboldi B, & Sacerdote P (2023). The Prokineticin System in Inflammatory Bowel Diseases: A Clinical and Preclinical Overview. Biomedicines, 11(11), 2985.
20. Mitrev N, Vande Casteele N, Seow C H, Andrews J M, Connor S J, Moore G T, & IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. (2017). consensus statements on therapeutic drug monitoring of anti‐tumour necrosis factor therapy in inflammatory bowel diseases. Alimentary pharmacology & therapeutics, 46(11-12), 1037-1053.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Haytham Nabil Alhazmi
King Fahad Hospital – Medinah – Saudi Arabia
Lama Zaki Al Nasrallah
Imam Abdulrahman Alfaisal Hospital - Al-Riyadh – Saudi Arabia
Zainab Abdullah Saad Abdullah
Qunfudah General Hospital - Al-Qunfudah – Saudi Arabia
Munirah Mohammed Hefzallah
Albade General Hospital – Tabuk – Saudi Arabia
Majed Abdullah Abutalib Alsayed
South Qunfudah General Hospital - Al-Qunfudah – Saudi Arabia
Wejdan Yahya Ahmed Hamoud
Qunfudah General Hospital - Al-Qunfudah – Saudi Arabia
Waleed Khaled Ali
Department of Infectious Disease Control - Jazan Health Cluster – Jazan
Khalid Mohammed Alzughaibi
Public health administration - jazan
Fahad Abdulaziz Ali Alsaadi
Eradah and Mental Health Complex – Jeddah
Ahmed Ali M Sultan
Health surveillance centers - Jeddah Islamic port - Jeddah
Loaie Jowed Bagadem
Department of Infectious Disease Control - Jazan Health Cluster – Jazan
Ahmed Ibrahim Muair
Department of Infectious Disease Control - Jazan Health Cluster – Jazan